Increased risk of fibrinolysis shutdown among severely injured trauma patients receiving tranexamic acid

Journal of Trauma and Acute Care Surgery

Volumn 84, Issue 3, 2018, Pages 426-432

  Meizoso, Jonathan P ^a   Dudaryk, Roman ^a   Mulder, Michelle B ^a   Ray, Juliet J ^a   Karcutskie, Charles A ^a   Eidelson, Sarah A ^a   Namias, Nicholas ^a   Schulman, Carl I ^a   Proctor, Kenneth G ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

antifibrinolytic; Coagulopathy; fibrinolysis; fibrinolysis shutdown; tranexamic acid

Indexed keywords

FRESH FROZEN PLASMA; TRANEXAMIC ACID; ANTIFIBRINOLYTIC AGENT;

ACUTE KIDNEY FAILURE; ACUTE LUNG INJURY; ADULT; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; BLUNT TRAUMA; COMPARATIVE STUDY; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICALLY ILL PATIENT; CRYOPRECIPITATE; DRUG INDUCED DISEASE; EMERGENCY HEALTH SERVICE; ERYTHROCYTE TRANSFUSION; FEMALE; FIBRINOLYSIS; FIBRINOLYSIS SHUTDOWN; FIBRINOLYTIC THERAPY; GLASGOW COMA SCALE; HUMAN; INJURY SCALE; INJURY SEVERITY; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; OBSERVATIONAL STUDY; PENETRATING TRAUMA; PRIORITY JOURNAL; RISK FACTOR; SHOCK; SYSTOLIC BLOOD PRESSURE; THROMBOELASTOGRAPHY; BLOOD; CLINICAL TRIAL; COMPLICATION; DOSE RESPONSE; DRUG EFFECT; FOLLOW UP; INJURY; MULTICENTER STUDY; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ANTIFIBRINOLYTIC AGENTS; BLOOD COAGULATION DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FIBRINOLYSIS; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; THROMBELASTOGRAPHY; TRANEXAMIC ACID; TRAUMA CENTERS; TRAUMA SEVERITY INDICES; TREATMENT OUTCOME; WOUNDS AND INJURIES;

EID: 85042913686     PISSN: 21630755     EISSN: 21630763     Source Type: Journal    
DOI: 10.1097/TA.0000000000001792     Document Type: Conference Paper

References (27)

1. CRASH-2 Trial Collaborators, Shakur H, Roberts I, Bautista R, Caballero J, Coats T, Dewan Y, El-Sayed H, Gogichaishvili T, Gupta S, et al. Effects of tranexamic acid on death, vascular occlusive events, blood transfusion in trauma patients with significant haemorrhage (CRASH-2): A randomised, placebo-controlled trial. Lancet. 2010;376(9734):23-32.
2. Ramirez RJ, Spinella PC, Bochicchio GV. Tranexamic acid update in trauma. Crit Care Clin. 2017;33(1):85-99.
3. Valle EJ, Allen CJ, Van Haren RM, Jouria JM, Li H, Livingstone AS, Namias N, Schulman CI, Proctor KG. Do all trauma patients benefit from tranexamic acid J Trauma Acute Care Surg. 2014;76(6):1373-1378.
4. CRASH-2 Collaborators, Roberts I, Shakur H, Afolabi A, Brohi K, Coats T, Dewan Y, Gando S, Guyatt G, Hunt BJ, et al. The importance of early treatment with tranexamic acid in bleeding trauma patients: An exploratory analysis of the CRASH-2 randomised controlled trial. Lancet. 2011;377(9771): 1096-1101, 101 e1-2.
5. Harvin JA, Peirce CA, Mims MM, Hudson JA, Podbielski JM, Wade CE, Holcomb JB, Cotton BA. The impact of tranexamic acid on mortality in injured patients with hyperfibrinolysis. J Trauma Acute Care Surg. 2015;78(5):905-909; discussion 909-11.
6. Moore HB, Moore EE, Gonzalez E, Chapman MP, Chin TL, Silliman CC, Banerjee A, Sauaia A. Hyperfibrinolysis, physiologic fibrinolysis, fibrinolysis shutdown: The spectrum of postinjury fibrinolysis and relevance to antifibrinolytic therapy. J Trauma Acute Care Surg. 2014;77(6):811-817; discussion 817.
7. Moore HB, Moore EE, Liras IN, Gonzalez E, Harvin JA, Holcomb JB, Sauaia A, Cotton BA. Acute fibrinolysis shutdown after injury occurs frequently and increases mortality: A multicenter evaluation of 2, 540 severely injured patients. J Am Coll Surg. 2016;222(4):347-355.
8. Brohi K, Singh J, Heron M, Coats T. Acute traumatic coagulopathy. J Trauma. 2003;54(6):1127-1130.
9. Mac Leod JB, Lynn M, Mc Kenney MG, Cohn SM, Murtha M. Early coagulopathy predicts mortality in trauma. J Trauma. 2003;55(1):39-44.
10. Moore HB, Moore EE, Huebner BR, Stettler GR, Nunns GR, EinAndersen PM, Silliman CC, Sauaia A. tranexamic acid is associated with increased mortality in patients with physiological fibrinolysis. J Surg Res. 2017;220: 438-443.
11. Meizoso JP, Karcutskie CA, Ray JJ, Namias N, Schulman CI, Proctor KG. PAndersistent fibrinolysis shutdown is associated with increased mortality in severely injured trauma patients. J Am Coll Surg. 2017 Apr;224(4): 575-582.
12. Greenfield LJ, Proctor MC, Rodriguez JL, Luchette FA, Cipolle MD, Cho J. Posttrauma thromboembolism prophylaxis. J Trauma. 1997;42(1):100-103.
13. Van Haren RM, Valle EJ, Thorson CM, Jouria JM, Busko AM, Guarch GA, Namias N, Livingstone AS, Proctor KG. Hypercoagulability and other risk factors in trauma intensive care unit patients with venous thromboembolism. J Trauma Acute Care Surg. 2014;76(2):443-449.
14. Van Haren RM, Thorson CM, Valle EJ, Busko AM, Guarch GA, Andrews DM, Pizano LR, Schulman CI, Namias N, Proctor KG. Hypercoagulability after burn injury. J Trauma Acute Care Surg. 2013;75(1):37-43.
15. Zou G. A modified Poisson regression approach to prospective studies with binary data. Am J Epidemiol. 2004;159(7):702-706.
16. Wafaisade A, Lefering R, Bouillon B, Böhmer AB, Gäßler M, Ruppert M. Trauma Register DGU. Prehospital administration of tranexamic acid in trauma patients. Crit Care. 2016;20(1):143.
17. Morrison JJ, Dubose JJ, Rasmussen TE, Midwinter MJ.Military Application of Tranexamic Acid in Trauma Emergency Resuscitation (MATTAnders) Study. Arch Surg. 2012;147(2):113-119.
18. Morrison JJ, Ross JD, Dubose JJ, Jansen JO, Midwinter MJ, Rasmussen TE. Association of cryoprecipitate and tranexamic acid with improved survival following wartime injury: Findings from the MATTAnders II Study. JAMA Surg. 2013;148(3):218-225.
19. Shiraishi A, Kushimoto S, Otomo Y, Matsui H, Hagiwara A, Murata K. Japanese Observational Study for Coagulation and Thrombolysis in Early Trauma (J-OCTET) investigators. Effectiveness of early administration of tranexamic acid in patients with severe trauma. Br J Surg. 2017;104(6): 710-717.
20. Roberts I, Edwards P, Prieto D, Joshi M, Mahmood A, Ker K, Shakur H. Tranexamic acid in bleeding trauma patients: An exploration of benefits and harms. Trials. 2017;18(1):48.
21. Moore EE, Moore HB, Gonzalez E, Sauaia A, Banerjee A, Silliman CC. Rationale for the selective administration of tranexamic acid to inhibit fibrinolysis in the severely injured patient. Transfusion. 2016;56(Suppl 2): S110-S114.
22. Cannon JW, Khan MA, Raja AS, Cohen MJ, Como JJ, Cotton BA, Dubose JJ, Fox EE, Inaba K, Rodriguez CJ, et al. Damage control resuscitation in patients with severe traumatic hemorrhage: A practice management guideline from the Eastern Association for the Surgery of Trauma. J Trauma Acute Care Surg. 2017;82(3):605-617.
23. Kozar RA, Peng Z, Zhang R, Holcomb JB, Pati S, Park P, Ko TC, Paredes A. Plasma restoration of endothelial glycocalyx in a rodent model of hemorrhagic shock. Anesth Analg. 2011;112(6):1289-1295.
24. Haywood-Watson RJ, Holcomb JB, Gonzalez EA, Peng Z, Pati S, Park PW, Wang W, Zaske AM, Menge T, Kozar RA. Modulation of syndecan-1 shedding after hemorrhagic shock and resuscitation. PLoS One. 2011; 6(8):e23530.
25. Kozar RA, Pati S. Syndecan-1 restitution by plasma after hemorrhagic shock. J Trauma Acute Care Surg. 2015;78(6 Suppl 1):S83-S86.
26. Moore HB, Moore EE, Gonzalez E, Wiener G, Chapman MP, Dzieciatkowska M, Sauaia A, Banerjee A, Hansen KC, Silliman C. Plasma is the physiologic buffer of tissue plasminogen activator-mediated fibrinolysis: Rationale for plasma-first resuscitation after life-threatening hemorrhage. J Am Coll Surg. 2015;220(5):872-879.
27. Meizoso JP, Karcutskie CA, Ray JJ, Namias N, Schulman CI, Proctor KG. PAndersistent fibrinolysis shutdown is associated with increased mortality in severely injured trauma patients. J Am Coll Surg. 2017;224(4):575-582.